Swarthmore, PA, United States of America

Xiaojun Liu

This inventor holds 19 USPTO granted patents and 11 published patent applications and 6 EPO patents. Top assignees: University of Pennsylvania, Novartis Ag. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaojun Liu. Retrieved from https://idiyas.com/inventor/xiaojun-liu-uj3dl6dp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 11)

% Patents Active = 100.0

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 81(Granted Patents)

Location History:

Swarthmore, PA (US) (2017 - 2022)
Wallingford, PA (US) (2020 - 2024)

Company Filing History:

19 out of 2,659

University of Pennsylvania

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760274 - COMPOSITIONS AND METHODS OF STIMULATING AND EXPANDING T CELLS (2026-10-13),

2. 12577567 - Altering Gene Expression in Modified T Cells and Uses Thereof (2026-03-17),

3. 12570982 - Altering Gene Expression in Modified T Cells and Uses Thereof (2026-03-10),

4. 12344843 - Altering gene expression in cart cells and uses thereof (2025-07-01),

5. 12227555 - Use of gene editing to generate universal TCR re-directed t cells for adoptive immunotherapy (2025-02-18),

6. 12215137 - Compositions and methods for T cell delivery of therapeutic molecules (2025-02-04),

7. 12162922 - Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules (2024-12-10),

8. 11992503 - Prostate-specific membrane antigen cars and methods of use thereof (2024-05-28),

9. 11795240 - Enhancing activity of CAR T cells by co-introducing a bispecific antibody (2023-10-24),

10. 11738047 - Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof (2023-08-29),

11. 11471487 - Compositions and methods of stimulating and expanding T cells (2022-10-18),

12. 11208661 - Altering gene expression in modified T cells and uses thereof (2021-12-28),

13. 11203758 - Altering gene expression in modified T cells and uses thereof (2021-12-21),

14. 11028143 - Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules (2021-06-08),

15. 10934336 - Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy (2021-03-02),

Title: Innovations and Contributions of Inventor Xiaojun Liu

Introduction

Xiaojun Liu, based in Swarthmore, PA, is a prominent inventor specializing in advancements in immunotherapy and gene editing. With an impressive portfolio of 15 patents, Liu's work focuses on enhancing T cell therapy, which has significant implications for cancer treatment and autoimmune diseases.

Latest Patents

Liu's latest patents showcase pioneering developments in the field of immunotherapy. One notable patent outlines the "Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy." This invention involves compositions and methods for creating modified immune cells with an inducible expression system. It provides novel approaches for utilizing gene-edited immune cells in T cell therapy, highlighting potential treatment methods that can significantly improve cancer therapy outcomes.

Another recent patent, titled "Compositions and methods for T cell delivery of therapeutic molecules," details methods for modifying T cells. This invention enables the introduction of nucleic acids coding for switch molecules and soluble fusion proteins, allowing T cells to transiently express specific therapeutic elements. This innovative approach opens new avenues for treating diseases such as cancer and autoimmune conditions through customized T cell modifications.

Career Highlights

Throughout his career, Xiaojun Liu has worked with prestigious organizations, including the University of Pennsylvania and Novartis AG. His contributions have significantly influenced the landscape of immunotherapy research and development, emphasizing the role of T cell modifications in modern medicine.

Collaborations

Liu has collaborated with esteemed colleagues such as Yangbing Zhao and Carl H. June, both of whom are also recognized for their contributions to immunotherapy. These partnerships have helped drive forward the research and practical applications of T cell therapies, capitalizing on the innovative techniques developed by Liu.

Conclusion

Xiaojun Liu stands out as a leading inventor in the field of immunotherapy, with his substantial patent portfolio reflecting a commitment to advancing medical science. Through his latest patents and fruitful collaborations, he continues to influence the future of cancer treatment and beyond, making significant contributions to the research community.

Profile summary based on public USPTO records.